1-4 of 4
Anil Singhal
Close
Sort by
Journal Articles

Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL

Richard R. Furman, MD, Leslie Andritsos, MD, Ian W. Flinn, MD, PhD, Andres Forero-Torres, MD, Kenneth A. Foon, MD, John M. Pagel, MD, PhD, Anil Singhal, MD, Scott C. Stromatt, MD, John C. Byrd, MD
Journal: Blood
Blood (2010) 116 (21): 56.
https://doi.org/10.1182/blood.V116.21.56.56
Published: 2010
Journal Articles

Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results.

Andrzej J Jakubowiak, William Bensinger, David Siegel, Todd M. Zimmerman, Jan M. Van Tornout, Carol Zhao, Anil Singhal, Kenneth Anderson
Journal: Blood
Blood (2009) 114 (22): 3876.
https://doi.org/10.1182/blood.V114.22.3876.3876
Published: 2009
Journal Articles

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

Sagar Lonial, Ravi Vij, Jean-Luc Harousseau, Thierry Facon, Jonathan Kaufman, Amitabha Mazumder, Philippe Moreau, Xavier Leleu, John Fry, Anil Singhal, Sundar Jagannath
Journal: Blood
Blood (2009) 114 (22): 432.
https://doi.org/10.1182/blood.V114.22.432.432
Published: 2009
Journal Articles

Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma

Jeffrey A. Zonder, Seema Singhal, William Bensinger, Ann Mohrbacher, Mohamad A. Hussein, Nikhil C. Munshi, Ingrid Caras, Anil Singhal, Frits van Rhee
Journal: Blood
Blood (2008) 112 (11): 2773.
https://doi.org/10.1182/blood.V112.11.2773.2773
Published: 2008